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of improving reﬁll rates. This leads to improved medica-
tion compliance and improved clinical outcomes. Because
selected medications were also formulary-preferred
agents, formulary compliance and volume within several
key therapeutic categories was enhanced.
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SURVIVAL ANALYSIS IN SEDATED INTENSIVE
CARE UNIT (ICU) PATIENTS
Chaikledkaew U1, Hopeﬂ AW2, Kamath TV3, Johnson KA1
1University of Southern California, Los Angeles, CA, USA;
2AmeriNet, St. Louis, MO, USA; 3Bristol-Myers Squibb
Company, Princeton, NJ, USA
OBJECTIVES: To compare survival in sedated ICU
patients by hospital type and to investigate various factors
associated with patient survival.
METHODS: Data from 622 patients admitted to the
ICU, intubated more than 24 hours, and receiving seda-
tives/analgesics during intubation were collected from 
42 hospitals from November 22, 1999 to March 4, 2000.
Patient demographic, sedative and analgesic selection,
and outcome data were recorded on standard data forms.
The Kaplan-Meier (KM) survival curves and the Cox pro-
portional hazard model were used to examine the effect
of hospital type and other factors on patient survival.
RESULTS: Patients in teaching hospitals had a signiﬁ-
cantly higher survival rate compared to community hos-
pitals (p < 0.02). The Cox regression analyses showed
that patient mortality was signiﬁcantly associated with
older age (hazard ratio; HR = 1.03), higher severity of
illness (HR = 1.04), having certain comorbid conditions
[lymphoma (HR = 2.87) and chronic hypoxia (HR =
2.57)], receiving analgesic agents (e.g., morphine, hydro-
morphone, and fentanyl) (HR = 2.76) and receiving care
in a community hospital (HR = 0.62). However, whether
the patient received treatment consistent with practice
guidelines for ICU sedation and was treated in a hospital
with a care plan for ICU sedation had no signiﬁcant
impact on patient survival in this analysis.
CONCLUSIONS: The results suggest that patients 
admitted to teaching hospitals seem to have better sur-
vival compared to community hospitals controlling for
other factors that impact patient outcomes. However,
whether this is due to hospital type, some other patient
care practice or patient factors needs to be determined.
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THERAPEUTIC INTERCHANGEABILITY OF
LEVOTHYROXINE
von Scheele B, Sherrill B, Gilsenan AW, Richter A, Devlin P
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVE: This evidence-based review evaluates the
therapeutic interchangeability of levothyroxine between
the original product Synthroid, and the two major 
generic brands Levoxyl and Levothroid, for use in
hypothyroidism.
METHODS: A literature search identiﬁed 8 bioequiva-
lence trials comparing different formulations of levothy-
roxine tablets. Meta-analyses were conducted to compare
average bioavailability using three pharmacokinetic mea-
sures (Total T4, Thyrotropin-stimulating Hormon [TSH],
and Free Thyroxine Index [FTI]). These measures were
also evaluated for differences in variability between treat-
ment groups.
RESULTS: The three formulations of Synthroid, Levoxyl,
and Levothroid can be expected to produce similar
average levels of circulating total T4 and TSH at steady
state. Due to limited data, this statement does not extend
to levels of free T4 nor free T3. Meta-analyses suggest
that differences may exist in the variability of effect 
of levothyroxine products. Speciﬁcally, individual TSH
levels in treated hypothyroid patients may span a wider
range with some products than with others. This vari-
ability may be due to true individual differences in the
variability of absorption of these products or to the use
of outdated assay techniques (ﬁrst generation radio-
immunoassay) and short study durations that do not
allow enough time for the patient to reach steady-state.
CONCLUSION: Studies generally suggest that Synthroid,
Levoxyl, and Levothroid are bioequivalent on average.
However, population (between subject) variability may 
be different across products. Establishment of individual
bioequivalence will require new, prospective studies of
adequate treatment duration that use the most sensitive
assay methodologies. Until such studies are undertaken,
current treatment guidelines that recommend hypo-
thyroid patients be reassessed 6 weeks after a change 
in brand or dose should remain in effect.
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USING THE AMERICAN PRODUCTIVITY AUDIT
(APA) TO INFORM EMPLOYERS ABOUT THE
WORK-RELATED COST OF HEALTH
CONDITIONS IN THEIR WORKFORCE
Matousek DM, Ricci J, Stewart W, Chee E
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OBJECTIVES: The American Productivity Audit (APA),
an on-going week-to-week telephone survey, provides
valid and reliable estimates of health-related work loss.
The APA is currently being used to generate tailored
reports for employers to inform them of the lost produc-
tive work time associated with speciﬁc health conditions.
The paper illustrates the process.
METHODS: We developed and validated the Work and
Health Interview (WHI) for APA administration. The
WHI quantiﬁes missed work hours and lost productive
time while at work for speciﬁc health conditions using
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two-week recall. Two measures were derived for each
condition—hours/worker/week of lost productive time
(LPT) and its dollar equivalent. Several derivation
methods were considered. We selected a conservative
method based on self-reported attribution for LPT. A
random sample of 13,252 workers 18–65 years of age
completed the WHI between July 2, 2001 and January 2,
2002. LPT was converted to dollars/worker/week using
self-reported annual salary. Tailored employer-speciﬁc
reports can be generated based on the characteristics of
an employer’s workforce including age, gender, occupa-
tion, and region. The illustration follows.
RESULTS: Company Y (n = 5,400) included 3,460 men
and 1,940 women with similar age distributions: 45%
18–34 years, 30% 35 to 44 years, 20% 45 to 54 years,
and 5% 55+ years. The ﬁve episodic/chronic-episodic
health conditions associated with the most LPT in
Company Y were cold/ﬂu (8.2%), headache (5.9%), low
energy (3.2%), back pain (3.1%), and digestive disorders
(2.8%). LPT attributed to each condition among those
affected was cold/ﬂu (0.42), headache (0.22), back pain
(0.21), low energy (0.14), and digestive disorders (0.12).
These ﬁve conditions potentially cost the employer an
estimated $5.1 million dollars/year in LPT.
CONCLUSIONS: The APA can be used to generate 
tailored reports for employers of health-related work 
loss. This is a ﬁrst step toward providing employers with
concrete estimates of the indirect cost of speciﬁc health
conditions.
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PREVENTABLE DRUG-RELATED MORBIDITY
AND MORTALITY IN OLDER ADULTS:
A CANADIAN COST-OF-ILLNESS MODEL
Kidney T, MacKinnon NJ
Dalhousie University, Halifax, NS, Canada
The cost of drug-related morbidity and mortality is stag-
gering, estimated to be $177 billion USD annually in the
United States. Much of this is preventable and occurs in
older adults.
OBJECTIVES: Given the lack of a Canadian cost-of-
illness model, our objective was to determine the eco-
nomic impact of preventable drug-related morbidity
(PDRM) in older adults in Canada from a public payer
perspective.
METHODS: A probability pathway model was devel-
oped for PDRM in older adults, based on a previously
published methodology. To determine the probabilities
that would be assigned to each branch of the pathway, a
panel of 25 health care professionals (12 general practi-
tioners, 4 clinical pharmacologists, 6 geriatricians, and 3
pharmacists) completed a written survey. Data from the
Population Health Research Unit (PHRU) at Dalhousie
University was primarily used to determine the costs that
were assigned to each outcome. Data analysis was con-
ducted by using Treeage (DATA,v3.5).
RESULTS: The cost-of-illness model estimated that the
annual cost of PDRM in older adults in Canada is $10.9
billion CAN. Admissions to long-term care were found
to be the biggest driver in the model, accounting for $6.7
billion CAN of the costs. One-way sensitivity analyses
were performed, varying the probability and cost esti-
mates, but the estimated total cost was relatively insensi-
tive to these changes.
CONCLUSIONS: The burden of PDRM is potentially
substantial in both the adverse clinical outcomes to the
patient and the economic impact to our health care
system. At an estimated annual cost of $10.9 billion,
PDRM in older adults is one of the more costly “illnesses”
in Canada, with a greater annual cost than either cancer
or respiratory diseases. This study represents a pro-
gression in the literature on cost-of-illness models by
focusing exclusively on (1) preventable drug-related mor-
bidities that (2) occur in older adults, in (3) Canada.
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PHARMACY BENEFIT RESOURCE UTILIZATION
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INDEMNITY INSURANCE PROGRAM FOR FIVE
FISCAL YEARS FROM 1996 TO 2001
Jacobs EW, Bui TT, Jenkins TL, Park A
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OBJECTIVES: Quantify the prevalence and magnitude 
of utilization of pharmacy beneﬁts in a public employees
indemnity insurance program.
METHODS: The study was a retrospective study of paid
pharmacy claims for an insured population of approxi-
mately 150,000 eligible members per month for ﬁve ﬁscal
years from July 1996 to June 2001. Eligibility and paid
pharmacy claims ﬁles were analyzed to determine the 
proportion of members who were recipients, intensity
(number of prescriptions) per recipient per year, phar-
macy reimbursement per prescription, and pharmacy
reimbursement cost per member per month. The data
were divided into twenty age groups and a sub-analysis
was performed to assess changes in proportion, intensity,
and pharmacy reimbursement for each age group over a
ﬁve-year period.
RESULTS: Over the ﬁve-year period, the proportion of
recipients to eligible increased 9.4% from 0.717 to 0.784;
intensity per recipient increased 13.9% from 16.5 to 
18.8 prescriptions per recipient per year; pharmacy reim-
bursement per prescription increased 51.2% from $40.17
to $60.74 per member per month. This led to an overall
increased cost per member per month over the ﬁve-year
period of 83.2% ($42.20 to $77.31). Intensity per recip-
ient and proportion of recipients increased greatly with
age. Recipients aged 10–14 received 5.8 prescriptions per
year while those aged 30–34 received 9.4, those aged
50–54 received 18.9, and those aged 70–74 received 30.1
prescriptions per year in ﬁscal year 2001. The proportion
of recipients to eligible increased from 0.593 to 0.730 to
0.834 to 0.946, respectively, for the age groups per the
ﬁscal year.
